Ibiden Co.,Ltd.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-92.2% vs price
Base Case (Median)
-83.9% vs price
Bull Case (75th pct.)
-71.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1173.71 | -93.9% | High (40%) |
| PE Comparable | $5440.48 | -71.7% | Medium (25%) |
| Growth Trajectory DCF | $5875.08 | -69.4% | Medium (20%) |
| Graham Number | $3080.91 | -83.9% | Low (10%) |
| EV/EBITDA | $5682.63 | -70.4% | Medium (20%) |
| EV/FCF | $20.70 | -99.9% | Medium (20%) |
| Earnings Power Value | $1839.03 | -90.4% | Medium (50%) |
Based on 7 out of 8 methods, 4062.T appears overvalued at the current price of $19195.00. The base case fair value of $3080.91 implies 83.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.